Slide 1: Q3 2024 Earnings Call
Q3 2024 Earnings Call November 7, 2024
Slide 2: Welcome and Introduction
Welcome and Introduction JOHN SCARLETT, MICHELLE JIM FAYE FELLER, ANDREW J. M.D. ROBERTSON ZIEGLER M.D. GRETHLEIN, PH.D. Chairman of the Board, Executive Vice President, Executive Vice President, Executive Vice President, Executive Vice President, President and Chief Chief Financial Officer and Chie
Slide 3: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation and question-and-answer session, there will be forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to: • the launch, commercial opportunity and therapeut
Slide 4: Introductory Remarks
Introductory Remarks John Scarlett, M.D. Chairman and Chief Executive Officer 4
Slide 5: We Are Well-Positioned to Build Long-Term Commercial Value with RYTELO (imetelstat)
We Are Well-Positioned to Build Long-Term Commercial Value with RYTELO (imetelstat) First full quarter of product revenue of $28.2 million in Q3 2024 exceeded expectations, demonstrating commercial execution, high unmet need in LR-MDS, and compelling RYTELO value proposition Review of EU MAA could b
Slide 6: Commercial Updates
Commercial Updates Jim Ziegler EVP, Chief Commercial Officer 6
Slide 7: Q3 2024 U.S. Launch Performance Highlights
Q3 2024 U.S. Launch Performance Highlights LR-MDS Unmet Need & Compelling RYTELO Value Proposition Payors responsible for ~70% U.S. Permanent $28.2M 388 ordering centers covered lives J-code net product revenue, from launch through have implemented becomes effective with demand Q3, representing ~45%
Slide 8: Financial Results
Financial Results Michelle Robertson EVP, Chief Financial Officer 8
Slide 9: Third Quarter 2024 Financial Highlights
Third Quarter 2024 Financial Highlights • $28.2 million net product revenue for first full quarter after U.S. launch • Total OpEx was $56.5 million in Q3 2024; expected to be approx. $260-270 million for full year • Received $250 million in gross proceeds from synthetic royalty and debt financings,
Slide 10: Medical and Clinical Updates
Medical and Clinical Updates Faye Feller, M.D. EVP, Chief Medical Officer 10
Slide 11: ASH 2024 Abstracts Highlight Potential of Imetelstat in Myeloid Hematologic Malignancies
ASH 2024 Abstracts Highlight Potential of Imetelstat in Myeloid Hematologic Malignancies • New analyses from the IMerge clinical trial suggest that imetelstat demonstrates RBC-transfusion related clinical activity and hemoglobin rises in patients with New analyses from LR-MDS with TD-anemia regardle
Slide 12: Closing Remarks
Closing Remarks John Scarlett, M.D. Chairman and Chief Executive Officer 12
Slide 13: Thank you!
Thank you! Contact: Investor Relations investor@geron.com 13
Slide 14: Third Quarter 2024 Financials
Third Quarter 2024 Financials GERON CORPORATION GERON CORPORATION Condensed consolidated statements of operations Condensed consolidated balance sheets THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30 DECEMBER 31 (In thousands, except share SEPTEMBER 30 SEPTEMBER 30 (In thousands) 2024 2023 and per
Slide 15: RYTELO Patent and Regulatory Exclusivity in the U.S. for LR-MDS Expected into 2037
RYTELO Patent and Regulatory Exclusivity in the U.S. for LR-MDS Expected into 2037 Expected Regulatory Exclusivities, Patent Terms and Patent Term Extensions RYTELO patents 12/27/2025 12/27/2030 03/15/2033 08/30/2037 listed in the FDA’s Orange Book 6/6/2024 6/6/2029 FDA confirmed LR-MDS Data/Mar
Slide 16: Q&A
Q&A CONFIDEN TI A L | 16